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Background: The apoB/apoA1 ratio has been reported to be associated with the metabolic syndrome (MetS), and
it may be a more convenient biomarker in MetS predicting. However, whether apoB/apoA1 ratio is a better
indicator of metabolic syndrome than other biomarkers and what is the optimal cut-off value of apoB/apoA1 ratio
as an indicator of metabolic syndrome in Chinese population remain unknown. Thus, we carried out the current
study to assess the predictive value of apoB/apoA1 ratio and determine the optimal cut-off value of apoB/apoA1
ratio for diagnosing MetS in a Chinese population.
Method: We selected 1,855 subjects with MetS and 6,265 individuals without MetS based on the inclusion and
exclusion criteria from the China Health Nutrition Survey (CHNS) in 2009. MetS was identified based on the
diagnostic criteria of International Diabetes Federation (2005). Logistic regression was used to estimate the
association between the apoB/apoA1 ratio and risk of MetS, and receiver operating characteristics (ROC) curve
analysis was performed to test the predictive value of apoB/apoA1 ratio and calculate the appropriate cut-off value.
Results: Compared with the lowest quartile of apoB/apoA1 ratio, subjects in the fourth quartile had a higher risk of MetS
in both men [odds ratio (OR) = 2.64, 95% confidence interval (CI) =1.82-3.83] and women (OR = 5.18, 95% CI = 3.87-6.92)
after adjustment for potential confounders. The optimal cut-off value of apoB/apoA1 ratio for MetS detection was 0.85 in
men and 0.80 in women. Comparisons of ROC curves indicated that apoB/apoA1 ratio was better than traditional
biomarkers in predicting MetS.
Conclusion: Our results suggest that, apoB/apoA1 ratio has a promising predictive effectiveness in detection of MetS. An
apoB/apoA1 ratio higher than 0.85 in men and 0.80 in women may be a promising and convenient marker of MetS.
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Metabolic syndrome (MetS) has become the fastest grow-
ing chronic disease worldwide [1-3], including China [4].
MetS is characterized as a cluster of risk factors for ath-
erosclerosis including abdominal obesity, glucose intoler-
ance, hypertension, hyper triglyceridaemia (TG) and low
high-density lipoprotein cholesterol (HDL-C), all of which
increase the risk of cardiovascular disease incidence and
mortality [5]. Total cholesterol (TC), TG and HDL-C* Correspondence: ck@zju.edu.cn
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unless otherwise stated.levels vary greatly with the dietary intake of fat, and more-
over, measurements of TG and HDL-C need an at least
12-hours fast in clinical practice, which is not convenient
for patients. Therefore, a more convenient biomarker with
comparable diagnostic value for replacement is meaning-
ful in clinic.
Apolipoprotein B (apoB) is present in atherogenic li-
poproteins including very-low-density lipoprotein (VLDL),
intermediate-density lipoprotein (IDL) and low density
lipoprotein (LDL). Apolipoprotein A1 (apoA1) is a major
constituent of HDL, an anti-atherogenic apolipoprotein
[6,7]. Thus, the apoB/apoA1 ratio could represent the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,







Age, mean (SD) 49.27(15.14) 55.72(12.68) <0.0001
Male, n (%) 49.48 36.71 <0.0001
BMIa, mean (SD) 22.43(2.96) 26.47(3.16) <0.0001
Urbanization index, % 66.61(19.40) 69.96(19.56) <0.0001




Education levels, % <0.0001
Illiteracy 21.63 29.23
Primary school 19.31 21.52










≤3 drink/month 12.26 8.83
1-2 drink/week 7.86 6.5
3-4 drink/week 4.08 3.74








History of CVD, % 1.82 3.4 <0.0001
Diabetes, % 3.71 19.76 <0.0001
Hypertension, % 21.82 59.35 <0.0001
abody mass index = weight (kg)/height (m2).
bcategorized by tertiles of gross household income at 19600.00 and
39799.12 yuan.
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teins. In the clinical setting, the apoB/apoA1 ratio can be
measured at any time without fasting [8]. It implies that the
apoB/apoA1 ratio may be a more convenient biomarker in
MetS predicting.
Recently, several studies have reported that the apoB/
apoA1 ratio is associated with metabolic syndrome in
different ethnical groups [7-11]. However, only few studies
with relative small sample size have evaluated the associ-
ation between the apoB/apoA1 ratio and MetS in the
Chinese population [9,10]. It remains unclear whether
apoB/apoA1 ratio is a better indicator for identifying meta-
bolic syndrome in the Chinese population, and there are no
optimal cut-off values of apoB/apoA1 ratio for Chinese
men and women yet.
To assess the association between apoB/apoA1 ratio
and risk of MetS, compare the predictive effectiveness of
apoB/apoA1 ratio with various lipid ratios in China and
calculate the optimal cut-off values of apoB/apoA1 ratio
for Chinese men and women, we analyzed the data from
the China Health and Nutrition Survey 2009 (CHNS
2009) in current study.
Results
Demographic characteristics of participants with or
without MetS
Demographic characteristics of the 1,855 participants with
MetS and 6,265 without MetS are shown in Table 1. The
prevalence of MetS in this study population was 22.8%.
All demographic characteristics except gross household
income were significantly different between the MetS and
control groups (P <0.01).
Biomarkers and components of MetS across quartiles of
apoB/apoA1 ratio
Table 2 presents the level of some clinical biomarkers for
MetS across apoB/apoA1 ratio quartiles. Rising trend was
observed in total cholesterol, uric acid, creatinine, ALT,
hs-CRP, waist circumference, fasting glucose, HOMA-IR,
systolic and diastolic blood pressure, LDL-C and triglycer-
ide and all components except for HDL across the apoB/
apoA1 ratio quartiles (P for trend < 0.001), while a nega-
tive relationship was found between apoB/apoA1 ratio
quartiles and HDL (P for trend < 0.001).
Association between apoB/apoA1 ratio and risk of MetS
Table 3 summarizes the associations between apoB/
apoA1 ratio and risk of MetS. We found a significant
association between higher apoB/apoA1 ratio and in-
creased risk of MetS. Compared with the lowest quar-
tile, subjects in the fourth quartile had a 4.24 fold
higher risk of MetS (Model 3). This significant associ-
ation was present in both men and women, but was
stronger among women (OR = 5.18, 95% CI = 3.87-6.92)than among men (OR = 2.64, 95% CI = 1.82-3.83). There
was evidence of a statistically significant monotonic
trend. (Ptrend values <0.001).
Diagnostic performances of apoB/apoA1 ratio
ROC analysis was performed to assess the diagnostic
value of apoB/apoA1 ratio for MetS. Overall, the opti-
mal cut-off value of apoB/apoA1 ratio for MetS detection
was 0.82, with a sensitivity of 71.0% and a specificity of
61.9% (AUC= 0.72, 95%CI 0.71-0.73). The optimal apoB/
apoA1 ratio cut-off values among men and women for
detecting MetS were 0.80 (AUC= 0.71, 95%CI 0.70-0.73)
and 0.84 (AUC = 0.73, 95%CI 0.72-0.74), respectively. The
sensitivities were 78.4% and 65.6%, the specificities were
Table 2 Biomarkers and components of MetS across quartiles of apoB/apoA1 ratio
Quartiles of apoB/apoA1 ratio
Q1 (<0.61) Q2 (0.61-0.78) Q3 (0.78-0.98) Q4 (≥0.98) Ptrenda
n 2036 2026 2035 2023
ApoB (g/l) 0.68 (0.19) 0.84 (0.18) 0.96 (0.19) 1.16 (0.23) <0.001
ApoA1 (g/l) 1.40 (0.58) 1.20 (0.25) 1.09 (0.22) 0.95 (0.18) <0.001
Total cholesterol(mmol/l) 4.26 (0.83) 4.63 (0.82) 4.96 (0.86) 5.55 (0.99) <0.001
Uric acid (mg/dl) 282.96 (94.33) 293.50 (89.19) 314.10 (109.13) 334.63 (115.38) <0.001
Urea (mmol/l) 5.34 (1.56) 5.42 (1.50) 5.48 (1.42) 5.47 (1.40) 0.225
Creatinine (umol/l) 83.48 (13.80) 85.07 (13.72) 86.55 (13.89) 88.93 (14.29) <0.001
ALT (u/l) 19.00 (11.48) 20.21(11.91) 22.81 (14.17) 25.39 (15.63) <0.001
hs-CRP 1.80 (5.08) 2.12 (6.42) 2.79 (12.55) 3.09 (5.37) <0.001
Waist circumference (cm) 78.07 (9.51) 81.35 (9.83) 84.11 (9.81) 87.21 (10.02) <0.001
Fasting glucose (mmol/l) 5.07 (1.01) 5.16 (1.06) 5.45 (1.55) 5.72 (1.81) <0.001
HOMA-IRb 2.77 (4.16) 3.23 (5.56) 3.89 (7.41) 4.64 (8.71) <0.001
Systolic BP (mm Hg) 120.39 (17.95) 123.42 (18.59) 125.51 (18.54) 129.15 (18.97) <0.001
Diastolic BP (mm Hg) 78.02 (11.28) 79.96 (11.03) 81.12 (11.15) 83.01 (11.36) <0.001
LDL-C (mmol/l) 2.27 (0.71) 2.81 (0.80) 3.11 (0.81) 3.70 (0.95) <0.001
HDL-C(mmol/l) 1.69 (0.42) 1.50 (0.53) 1.33 (0.37) 1.22 (0.47) <0.001
Triglyceride (mmol/l) 1.22 (1.25) 1.40 (1.20) 1.83 (1.57) 2.21 (1.64) <0.001
alinear trend was adjusted by age and gender. P of age was adjusted by gender only. P of gender was adjusted for age only.
bHOMA-IR = fasting insulin(FINS)[mU/L] × fasting plasma glucose (FPG)[mmol/L])/22.5.
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potential confounders, the ORs in participants with an
apoB/apoA1 ratio >0.82 overall, >0.80 in men, and > 0.84 in
women were 2.71 (95%CI = 2.37-3.10), 2.18(95%CI = 1.76-
2.71), and 2.73 (95%CI = 2.31-3.24), respectively. Most of
the ORs remained significant when stratified by age, glucose
status, history of CVD and obesity status (Table 4). Similarly,Table 3 Adjusted ORs (95% CI) for the associations between a
Quartiles of a
Models Q1 (<0.61) Q2 (0.61-0.78)
All subjects
Model 1a Reference 1.40 (1.11-1.76)
Model 2b Reference 1.37 (1.08-1.73)
Model 3c Reference 1.35 (1.06-1.73)
Men
Model 1a Reference 1.04 (0.69-1.57)
Model 2b Reference 0.98 (0.64-1.48)
Model 3c Reference 0.94 (0.61-1.45)
Women
Model 1a Reference 1.58 (1.19-2.09)
Model 2b Reference 1.58 (1.19-2.11)
Model 3c Reference 1.58 (1.17-2.14)
aModel 1 was adjusted by age, gender and BMI.
bbased on Model 1, Model 2 was additionally adjusted by smoking, drinking, urban
household income per year.
cbased on Model 2, Model 3 was additionally adjusted by history of CVD, hypertensmost of the ORs for components of MetS were also signifi-
cant after adjusted for the covariates mentioned above.
Furthermore, to check whether the apoB/apoA1 ratio
was better than other biomarkers for MetS detection, we
also compared AUC of their ROC curves (Table 5). The
AUC of apoB/apoA1 ratio was significantly higher than
other lipid biomarkers (P < 0.001).poB/apoA1 ratio and risk of MetS
poB/apoA1 ratio
Q3 (0.78-0.98) Q4 (≥0.98) Ptrend
2.57 (2.07-3.19) 4.30 (3.48-5.32) <0.0001
2.59 (2.08-3.23) 4.28 (3.44-5.31) <0.0001
2.69 (2.13-3.89) 4.24 (3.37-5.32) <0.0001
1.96 (1.36-2.84) 2.92 (2.05-4.16) <0.0001
1.97 (1.36-2.87) 2.89 (2.01-4.13) <0.0001
1.93 (1.31-2.85) 2.64 (1.82-3.83) <0.0001
2.74 (2.10-3.58) 4.95 (3.78-6.47) <0.0001
2.79 (2.12-3.66) 4.93 (3.75-6.48) <0.0001
2.99 (2.24-4.00) 5.18 (3.87-6.92) <0.0001
ization index, educational levels, dietary energy intake everyday, gross
ion, diabetes.
Figure 1 Receiver operating characteristic curve of apoB/A1 ratio for metabolic syndrome (MetS) in men (a) and women (b).
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In this study, we estimated the association between apoB/
apoA1 ratio and metabolic syndrome in a relatively large
Chinese population, compared the predictive effectiveness
of apoB/apoA1 ratio with various traditional lipid ratios,Table 4 ORs (95% CI) for MetS and individual components ba
All subjects
OR (95% CI) P
ORa for MetS
Overall 2.71 (2.37-3.10) <0.001 2
Age category
<50 2.65 (2.12-3.31) <0.001 2
≥50 2.62 (2.21-3.09) <0.001 1
Glucose status
NGT 3.27 (2.73-3.92) <0.001 2
IFG 1.68 (1.27-2.23) <0.001 1
Diabetes 1.66 (1.05-2.63) 0.03 1
History of CVD
No 2.70 (2.36-3.09) <0.001 2
Yes 3.21 (1.52-7.25) <0.001 5.
Obesity statusb
BMI < 24 2.68 (2.11-3.39) <0.001 1
BMI≥ 24 2.50 (2.13-2.93) <0.001 2
ORa for componentsc
Waist 1.33 (1.17-1.51) <0.001 1
Glucose 1.52 (1.36-1.70) <0.001 1
BP 1.21 (1.09-1.35) <0.001 1
TG 2.82 (2.54-3.13) <0.001 2
HDL-C 4.01 (3.57-4.51) <0.001 3
aall ORs were adjusted for age, gender, BMI, smoking, drinking, urbanization index, edu
bChinese criterion.
call events are defined according to IDF 2005 criteria (see Methods for details).and calculated the optimal cut-off value of apoB/apoA1
ratio in a Chinese population.
We found a significant association between higher apoB/
apoA1 ratio and risk of MetS. Compared with the lowest
quartile, subjects in the fourth quartile ratio had a highersed on the optimal cut-off value of ApoB/apoA1 ratio
Men Women
OR (95% CI) P OR (95% CI) P
.18 (1.76-2.71) <0.001 2.73 (2.31-3.24) <0.001
.52 (1.80-3.53) <0.001 2.75 (2.05-3.68) <0.001
.95 (1.47-2.60) <0.001 2.68 (2.17-3.30) <0.001
.59 (1.90-3.54) <0.001 3.01 (2.42-3.75) <0.001
.35 (0.87-2.11) 0.182 1.92 (1.32-2.80) <0.001
.31 (0.71-2.40) 0.386 3.89 (1.16-4.90) 0.018
.13 (1.71-2.66) <0.001 2.74 (2.31-3.26) <0.001
41 (1.44-20.35) 0.012 2.50 (0.80-7.79) 0.114
.54 (0.95-2.50) 0.082 3.30 (2.50-4.36) <0.001
.22 (1.74-2.82) <0.001 2.33 (1.88-2.88) <0.001
.29 (1.06-1.57) 0.011 1.24 (1.04-1.46) 0.015
.52 (1.29-1.79) <0.001 1.53 (1.31-1.79) <0.001
.15 (0.99-1.34) 0.077 1.12 (0.96-1.29) 0.153
.41 (2.07-2.81) <0.001 2.93 (2.53-3.40) <0.001
.90 (3.20-4.75) <0.001 3.92 (3.39-4.53) <0.001
cational levels, dietary energy intake everyday, gross household income per year.
Table 5 Diagnostic performances of different indicators
All subjects Men Women
AUCa Pb AUCa Pb AUCa Pb
ApoB/apoA1 0.72 (0.71-0.73) Standard 0.71 (0.70-0.73) Standard 0.73 (0.72-0.74) Standard
ApoB 0.68 (0.67-0.69) <0.001 0.66 (0.64-0.68) <0.001 0.69 (0.68-0.70) <0.001
ApoA1 0.61 (0.59-0.62) <0.001 0.62 (0.61-0.64) <0.001 0.61 (0.59-0.62) <0.001
LDL 0.56 (0.55-0.58) <0.001 0.54 (0.52-0.55) <0.001 0.58 (0.56-0.59) <0.001
HDL/LDL 0.70 (0.69-0.71) <0.001 0.68 (0.66-0.69) <0.001 0.72 (0.71-0.74) 0.569
aarea under curve.
bp value for the comparison with AUC of ApoB/apoA1, and modified by the method of Sidak.
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poproteins are structural and functional proteins in the
lipoprotein particles. ApoB and apoA1, main constituents
of atherogenic and anti-atherogenic lipoproteins, play im-
portant roles in cholesterol and lipid transportation [6,7].
A number of prospective studies have shown that high
apoB/apoA1 ratio may be a promising marker for predict-
ing the occurrence of future cardiovascular events, such as
myocardial infarction and stroke [11,12]. In addition,
ApoB concentration and apoB/apoA1 ratio were found to
be associated with risk of MetS and its components and
were independent of conventional risk factors in several
previous studies [7,9,13-15]. Our results were consistent
with these findings.
Few studies have focused on the appropriate cut-off
values for MetS diagnosis in these study populations. Pit-
savos C et al. [16] suggested a ratio of 0.73 as an optimal
cut-off for predicting MetS, with a sensitivity of 74% and a
specificity of 67% in a Greek population. Chang et al. [17]
reported the sex-specific optimal apoB/apoA1 ratio cut-off
values in their study, 0.65 in men and 0.62 in women. In
addition, an apoB/apoA1 ratio of more than 0.7 in men
and 0.6 in women was indicated by Walldius [11] as a
signal of subsequent occurrence of myocardial infarction.
In the current study, optimal cut-off values calculated for
diagnosing metabolic syndrome were 0.82 in all subjects,
0.85 in men, and 0.80 in women, respectively. In consist-
ence with previous studies, these cut-off values remained
their diagnostic utility in most situations after stratification
by potential confounding factors such as age and obesity
status. In our study, however, the cut-off values are likely
to be higher than those reported in previous studies. One
possible explanation of the discrepancy is that our study
had a higher median of apoB/apoA1 ratio compared with
other studies, with evidence of a higher apoB level and a
lower apoA1 level in the current population (Table 2). Fur-
thermore, it has been reported that prevalence of MetS in
Asians is higher than that in Caucasians after adjustment
for body size [18]. Studies showed accumulation of intra-
abdominal fat is easier among Asian people [13,14], which
may also implied a higher average lipid level in serum
among Asians people including Chinese.The comparisons of ROC curves suggested that apoB/
apoA1 ratio, as a marker of MetS, was better than other
traditional biomarkers. To our knowledge, only one large
cross-sectional study has compared the diagnostic values
of different lipid ratios for MetS prediction in Korea, sug-
gesting that non-HDL-C/HDL ratio might be a better pre-
dictor, which was also confirmed in our study. However,
TC, TG and HDL-C levels vary greatly with the dietary in-
take of fat, and the measurements of TG and HDL-C need
an at least 12-hour fast in clinical practice which is incon-
venient for patients in clinic. Therefore, the non-HDL-C/
HDL ratio calculated according to TC and HDL levels is
also not convenient in clinic. In contrast, measurements
of apoB and apoA1 do not require fasting samples and
their measurement methods are internationally standard-
ized in reference materials traceable to the World Health
Organization. Therefore, apoB/apoA1 ratio could still be
an easily accessible tool instead of TG or HDL.
Several limitations of this study deserve mention.
First, the causal relationship between apoB/apoA1 ratio
and risk of MetS cannot be conclusively determined due
to the cross-sectional design. Second, we lacked infor-
mation about previous treatment on HDL-C or trigly-
ceride, which might influence the diagnosis of MetS.
Finally, owing to the design of CHNS, we could not valid-
ate the predictive value of apoB/apoA1 ratio in another
independent population. Despite of these limitations, this
is the first study to compare the predictive effectiveness of
apoB/apoA1 ratio with various traditional lipid ratios and
suggest optimal cut-off value of apoB/apoA1 ratio in iden-
tifying subjects with MetS in China. Our sample size was
large for detecting associations between apoB/apoA1 ratio
and risk of MetS.
In conclusion, the present study provides the first
evaluation of optimal cut-off values of apoB/apoA1 ratio
in identifying MetS patients in Chinese population. We
found that apoB/apoA1 ratio was associated with risk of
MetS and observed a better predictive effectiveness of
apoB/apoA1 ratio compared with other traditional lipid
biomarkers, perhaps reflecting a promising and con-
venient biomarker for diagnosing MetS. However, add-
itional studies are needed to confirm these findings.
Jing et al. Lipids in Health and Disease 2014, 13:81 Page 6 of 7
http://www.lipidworld.com/content/13/1/81Method
Study population
Subjects were selected from the CHNS 2009. Details of
the CHNS 2009 have been described elsewhere [15,19,20].
In brief, CHNS, an ongoing large-scaled and household-
based survey, started in 1989 and followed up every 2–4
years [19]. A stratified multistage, random cluster method
was used as a sampling strategy in nine provinces that vary
substantially in geography, economic development, public
resources (including Heilongjiang, Liaoning, Shandong,
Jiangsu, Henan, Hubei, Hunan, Guizhou and Guangxi),
covering nearly 56% of the whole Chinese population.
A total of 9,511 records of fasting blood information
from different participants were obtained in the dataset
of CHNS2009. The exclusion criteria for selecting sub-
jects were: (i) age < 18 years old (n = 845); (ii) pregnant
women (n = 62); (iii) apoB/apoA1 ratio >3 (n = 10);
abnormal kidney (serum creatinine >130 mmol/l in men
or >120 mmol/l in women), abnormal liver function
(ALT, TP, ALB ≥2.5*upper limit of normal value); (vi) in-
dividuals who had Thyromegaly (n = 9), cancer (n = 5),
urinary system disease (n = 21). In addition, we also ex-
cluded the subjects whose diagnostic information for MetS
was missing. Finally, 1,855 participants with MetS and
6,265 individuals without MetS were included in our study.
The study was approved by institutional review board
from the University of North Carolina at Chapel Hill, the
National Institute of Nutrition and Food Safety, China-
Japan Friendship Hospital, the Chinese Center for Disease
Control and Prevention, and Ministry of Health. Every
participant provided a written informed consent.
Definition of metabolic syndrome
MetS was defined according to the diagnostic criteria of
International Diabetes Federation in 2005. Participants
were diagnosed as MetS patients when they suffered
from central obesity (waist circumference ≥90 cm in
men and ≥80 cm in women), and met two or more of
the following criteria: (i) triglyceride level ≥150 mg/dl
(1.7 mmol/L) or specific treatment for its abnormality;
(ii) HDL-C level <40 mg/dl (1.03 mmol/L) in men
or <50 mg/dl (1.29 mmol/L) in women or specific
treatment for its abnormality; (iii) systolic blood pres-
sure (SBP) ≥130 mmHg and/or diastolic blood pressure
(DBP) ≥85 mmHg or treatment of previously diagnosed
hypertension and (iv) fasting glucose level ≥100 mg/dl
(5.6 mmol/L) or previously diagnosed type 2 diabetes.
Additional file 1: Figure S1 shows the details of subject
selection.
Measurement for variables used in analysis
Height and weight were measured when subjects were
wearing light indoor clothing without shoes. Body mass
index (BMI) was calculated as weight in kilograms dividedby the square of height in meters. Waist circumference
(WC) was measured at a level midway between the costal
margin and the iliac crest at the end of a normal expir-
ation. Blood pressure was measured in the right arm
with the use of a mercury sphygmomanometer after
the participant had been sitting quietly for five minutes.
Urbanization index was categorized according to its quar-
tiles and calculated from 12 components, covering social,
cultural, economic and community-level physical environ-
ments across time and place [19]. Gross household
income was grouped as low, median and high levels based
on the tertiles. Educational background was classified as
illiteracy, primary school, junior high school, senior high
school and higher levels. Smoking status was categorized
as never, current and ever. Alcohol drinking was defined
as follows: never, ≤3 drink/month, 1–2 drink/week, 3–4
drink/week and almost everyday.
For each participant, an overnight fasting blood sam-
ple was drawn by venipuncture. Serum glucose was
tested immediately in the local hospitals Serum glu-
cose, Triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C) apoB and apoA1 were measured by GPO-PAP,
enzymatic methods, and Immunoturbidimetric methods
(Hitachi 7600 automated analyzer, Kyowa, Japan), re-
spectively. Details of laboratory analysis were reported
in “China Health and Nutrition Survey (CHNS), Man-
ual for Specimen Collection and Processing” (http://
www.cpc.unc.edu/projects/china/data/datasets/Blood%
20Collection%20Protocol_English.pdf ) and “A list of




Continuous variables were expressed as mean ± SD, and
categorical variables were calculated as proportion (%).
Student’s t-test and Chi-square test were used to compare
the continuous and categorical demographic characteris-
tics between subjects with and without MetS, respectively.
All participants were categorized into four groups accord-
ing to the quartiles of apoB/apoA1 ratio in the controls.
Biochemical characteristics of the population across the
apoB/apoA1 quartiles were compared using one-way ana-
lysis of variance (ANOVA). Linear regression was used to
assess the association between the apoB/apoA1 ratio and
other biomarkers in serum. We used unconditional logis-
tic regression models to estimate the odds ratios (ORs)
and 95% confidence intervals (CIs). We used three models
to estimate the association between apoB/apoA1 ratio and
risk of MetS, and different confounding factors were in-
cluded for adjustment in these three models, respectively.
In addition, receiver operating characteristics (ROC) curve
was performed to calculate the area under the curve
(AUC), evaluating the diagnostic value of apoB/apoA1
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termined by Youden index [21] (sensitivity + specificity - 1).
Furthermore, we conducted a ROC comparison analysis to
compare the utility of apoB/apoA1 ratio with other bio-
markers for identifying MetS. The AUC and optimal
points were determined using MedCalc version 11.4.2.0
for Windows (MedCalc Software, Mariakerke, Belgium).
All data analyses except ROC analysis were conducted
using STATA version 11.0 (STATA Corp, College Station,
Texas) and SAS version 9.2 (SAS Institute Inc., Cary, NC).
All tests were two sided and P < 0.05 was considered sta-
tistically significant.
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